1
Return

Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model

delete2026-07-21
delete0
delete
OA
AI
G
Germana Cocozza
T
Tiziano D’Andrea
M
Martina Di Rocco
L
Ludovica Maria Busdraghi
G
Gilda Chila
X
Xingzi Lin
E
Enrico Lanza
F
Fanny Collaud
F
Francesca C. Follo
C
Clelia Buccheri
V
Viola Folli
G
Giuseppe Ronzitti
F
Ferdinando Scavizzi
M
Marcello Raspa
V
Vincenzo Leuzzi
V
Vladimir L. Katanaev
S
Serena Galosi
S
Sergio Fucile
S
Simone Martinelli
G
Giuseppina D’Alessandro *
C
Cristina Limatola *
DOI:10.1186/s40478-026-02389-6delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The heterotrimeric G proteins are ubiquitous membrane-bound complexes specialized in the transduction of receptor-mediated extracellular signals into intracellular responses. Mutations in the G protein subunit alpha O1 (Gαo), encoded by GNAO1, have been associated with neurodevelopmental disorders characterized by prominent movement disorder with or without epilepsy. The Gnao1[C215Y]/+ mouse model recapitulates key features of the human disease, with a relatively mild phenotype, normal viability and late onset movement abnormalities, detectable in specific motor tasks. Here we report functional alterations in cortical layer V pyramidal neurons from Gnao1[C215Y]/+ mice, with reduction of the inward currents (Ih) and impairment of the GABAB-mediated outward current. We propose an adeno-associated virus (AAV)-based gene therapy aimed at overexpressing the wild-type form of Gαo by intracerebroventricular injection in newborn heterozygous Gnao1[C215Y]/ + mice. Our results demonstrate that overexpression of the wild-type protein mitigates behavioral abnormalities and restores functional neuronal deficits in young adult mice, thereby supporting the development of AAV-mediated gene augmentation strategies to counteract the effects of GNAO1 variants in patients. The potential of gene supplementation therapy is further supported by data from genetically modified C. elegans strains carrying not only the relatively mild C215Y variant but also a panel of goa-1/GNAO1 mutations associated with more severe phenotypes, suggesting a broader potential of this therapeutic strategy.
Keywords:
GNAO1
Gαo
Gene therapy
Behavioral tests
Mouse model
Electrophysiological recordings
C. elegans

Journal

Acta Neuropathologica Communications cover
Acta Neuropathologica Communications
IF:
5.7
Papers:
2.3K
Citations:
1.0W

Organization

N
national research council
Scholars:
1.6K
Papers: 659
Citations: 0
D
Department of Physiology and Pharmacology
Scholars:
175
Papers: 68
Citations: 0
U
Universite Paris-Saclay
Scholars:
925
Papers: 311
Citations: 0
D
Department of Human Neuroscience
Scholars:
51
Papers: 19
Citations: 0
T
translational research center in oncohaematology
Scholars:
2
Papers: 1
Citations: 0
D
department of oncology and molecular medicine
Scholars:
14
Papers: 3
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers